Follow-up of Patients With Inflammatory Myopathies Associated With a Biobank

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jul 7, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on understanding inflammatory myopathies, which are rare muscle diseases that can be caused by various factors, including genetics and medications. Researchers aim to build a group of patients (called a cohort) and collect biological samples (known as a biobank) from them. This will help scientists study what causes these conditions and how they can be treated more effectively. By analyzing different aspects of the disease, including symptoms and organ involvement, the trial seeks to identify ways to predict how patients might respond to treatment.

To participate in this study, individuals must be at least 18 years old and have a suspected case of myositis, such as dermatomyositis or polymyositis, among others. They should also agree to allow their health data to be used for research purposes. Participants will help contribute to important research that could lead to better understanding and potential cures for these conditions. Overall, this trial is an opportunity for patients to play a vital role in advancing scientific knowledge about their diseases.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Suspicion of Myositis defined according to reference classifications: Dermatomyositis (DM), polymyositis (PM) defined as early as 1975 by Bohan and Peter, inclusion myositis (IM) according to the criteria of Griggs et al, 1995 and autoimmune necrotizing myopathy (ANM) by Hoogendijk et al, in 2004 and iatrogenic (e.g. drug-induced) myositis.
• • No opposition from patients to the use of their data
• • Signature of consents for the constitution of the biobank and the genetic analyses
• Exclusion Criteria:
• • Patients under AME
• • Patients under legal protection